Pituitary adenoma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DIS-PITUITARY-ADENOMA`
Type	Disease
Aliases	Corticotroph adenomaMEN1-associated pituitary adenomaNonfunctioning pituitary adenomaPitNETPituitary neuroendocrine tumorProlactinomaSomatotroph adenomaАденома гіпофіза
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-CNS-2025` `SRC-NCCN-NET-2025`

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology	8272/0
icd_o_3_topography	["C75.1"]
icd_10	D35.2
who_classification	WHO Endocrine and Neuroendocrine Tumours 5th ed (2022) + CNS 5th ed (2021): Pituitary neuroendocrine tumor (PitNET) lineage-based classification — lactotroph / somatotroph / corticotroph / thyrotroph / gonadotroph / null-cell

Capabilities

Notes

Functional adenomas classified by lineage / hormone hypersecretion; treatment is endocrine-cohort-specific: prolactinoma — dopamine agonists (cabergoline > bromocriptine) first-line, surgery for resistant / intolerant; somatotroph (acromegaly) — transsphenoidal surgery first-line, somatostatin analogs (octreotide LAR, lanreotide, pasireotide LAR), GH-receptor antagonist (pegvisomant) for residual; corticotroph (Cushing disease) — surgery, pasireotide, ketoconazole / metyrapone / osilodrostat for cortisol control; nonfunctioning — surgery for mass effect / visual compromise. MEN1 carriers: cascade screening from age 5 (prolactin + IGF-1 + serum Ca + intact PTH + fasting gastrin + pituitary MRI per protocol).

Used By

Algorithms

ALGO-MEN1-CARRIER-SURVEILLANCE - ALGO-MEN1-CARRIER-SURVEILLANCE
ALGO-PITUITARY-ADENOMA-1L - ALGO-PITUITARY-ADENOMA-1L

Disease

DIS-PARATHYROID-CARCINOMA - Parathyroid carcinoma
DIS-PITUITARY-BLASTOMA - Pituitary blastoma

Drug

DRUG-CABERGOLINE - Cabergoline
DRUG-PASIREOTIDE - Pasireotide

Indication

IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA - IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA
IND-PITUITARY-ADENOMA-1L-CUSHING-SURGERY-MEDICAL - IND-PITUITARY-ADENOMA-1L-CUSHING-SURGERY-MEDICAL
IND-PITUITARY-ADENOMA-1L-NFPA-SURGERY-MASS-EFFECT - IND-PITUITARY-ADENOMA-1L-NFPA-SURGERY-MASS-EFFECT
IND-PITUITARY-ADENOMA-1L-PROLACTINOMA-CABERGOLINE - IND-PITUITARY-ADENOMA-1L-PROLACTINOMA-CABERGOLINE

Red flag

RF-PITUITARY-MASS-EFFECT-VISUAL-COMPROMISE - Pituitary adenoma (typically nonfunctioning macroadenoma) causing compressive mass effect...

Regimen

REG-CABERGOLINE-PROLACTINOMA - Cabergoline for prolactinoma (dopamine agonist, first-line)
REG-PASIREOTIDE-CUSHING - Pasireotide for Cushing disease (pituitary-directed medical therapy)
REG-SSA-ACROMEGALY - Somatostatin analogue for acromegaly (lanreotide first-generation SSA; pasireotide for SS...